Addus (ADUS) Q4 2025 Earnings Call Transcript

Addus HomeCare reported strong Q4 2025 results, with revenue up 25.6% to $373.1 million, adjusted EPS up 28.3% to $1.77, and adjusted EBITDA up 33.3% to $50.3 million. Full-year revenue rose 23.2% to about $1.4 billion, supported by four personal care acquisitions, 6.3% same-store growth in personal care, and 16% same-store growth in hospice. Management also guided to continued acquisition activity, benefits from Illinois and potential New Mexico rate increases, but flagged a roughly 120 bps sequential gross margin decline in Q1 2026.

Analysis

ADUS is becoming less a single-segment labor provider and more a leveraged platform on state-funded home-based care density. The subtle bull case is that every incremental rate increase and M&A bolt-on improves fixed-cost absorption in G&A, while the company’s compliance and data infrastructure should widen the moat as states intensify fraud scrutiny. That makes smaller mom-and-pop agencies the likeliest losers: they face the same wage and compliance pressure without ADUS’s scale, funding access, or tech rollout cadence.

The market may underappreciate the second-order effect of the caregiver app and scheduling/AI initiatives: the real margin upside is not just higher service percentages, but lower churn, faster onboarding, and more flexible labor deployment across geographies. In a labor market that is no longer broken, operational software becomes a balance-sheet asset because it converts wage inflation from a pure headwind into a routing and utilization problem. If Texas and Illinois adoption follows the Illinois playbook, the earnings mix should increasingly reward process efficiency rather than only top-line rate relief.

The main near-term risk is not demand; it is margin optics. Q1 should look mechanically softer from merit and payroll-tax resets, and investors could overreact if they focus on sequential gross margin compression instead of the full-year revenue step-up from Illinois and potential New Mexico flow-through in H2. The deeper risk is policy timing: if 80/20 repeal chatter slips or states delay reimbursement actions, the multiple can compress even while fundamentals remain intact. Conversely, successful passage of New Mexico increases and continued capex-light acquisition cadence could re-rate the stock as a compounding roll-up rather than a simple Medicaid exposure name.

Key Decisions for Investors

• Long ADUS on weakness into the expected Q1 gross-margin dip; use a 3-6 month horizon and size for a 10-15% pullback entry if the market over-penalizes seasonal compression. Upside comes from H2 rate realization and acquisition cadence, which should re-accelerate EBITDA leverage.
• Pair trade: long ADUS / short a basket of smaller private-pay or Medicaid-heavy home-care operators with weaker scale and compliance infrastructure. Thesis: policy scrutiny and wage pressure should widen the gap between scaled operators and subscale peers over the next 6-12 months.
• Buy ADUS calls or call spreads into the Illinois/New Mexico legislative window; the catalyst is not headline growth but a step-up in forward visibility on state reimbursement and a cleaner 2026 earnings path. Best risk/reward if implied vol stays moderate before H2 policy decisions.
• Avoid chasing the stock immediately after rate-increase headlines; wait for confirmation that New Mexico pass-throughs are flowing through without margin erosion. If pass-through discipline is too aggressive, the market may revise down the incremental margin contribution.
• Monitor any retreat in ARPA-funded collections and DSO normalization as a liquidity check; if working capital stops improving, reduce exposure because the multiple depends on cash conversion staying strong.